{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T03:10:51Z","timestamp":1769224251705,"version":"3.49.0"},"reference-count":49,"publisher":"American Society for Microbiology","issue":"3","license":[{"start":{"date-parts":[[2009,3,1]],"date-time":"2009-03-01T00:00:00Z","timestamp":1235865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2009,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Resistance of influenza viruses to antiviral drugs can emerge following medication or may result from natural variation. Two classes of anti-influenza virus drugs targeting either the M2 protein (amantadine and rimantadine) or neuraminidase (NA; oseltamivir and zanamivir) are currently licensed. These drugs are expected to be important in controlling the early stages of a potential pandemic. In the present study, we describe how a pyrosequencing method can be used to rapidly detect established molecular markers of resistance to M2 blockers and NA inhibitors in influenza A (H5N1) viruses. The residues L26, V27, A30, S31, and G34 in the M2 protein were targeted for pyrosequencing. The NA residues for pyrosequencing analysis included the established markers of drug resistance (H274 and N294), as well as residues of less certain relevance (V116, I117, Q136, K150, and I222). A single pair of pyro-reverse transcription (RT)-PCR primers was designed to allow amplification of an approximately 600-nucleotide-long amplicon of the NA genes of H5N1 viruses from various clades\/subclades associated with infections in humans. The sensitivity of the assay was demonstrated by the successful pyrosequencing of RNA extracted from samples of serially diluted (10<jats:sup>\u22125<\/jats:sup>to 10<jats:sup>\u22127<\/jats:sup>) virus stocks with initial concentrations ranging from 10<jats:sup>5<\/jats:sup>to 10<jats:sup>8<\/jats:sup>PFU\/ml. The markers of resistance were detected in samples with threshold cycle values ranging from 32 to 37, as determined by real-time RT-PCR. The pyrosequencing approach may provide a valuable tool for rapid detection of markers of drug resistance in H5N1 viruses and facilitate the elucidation of the role of such changes in natural and acquired drug resistance.<\/jats:p>","DOI":"10.1128\/aac.01446-08","type":"journal-article","created":{"date-parts":[[2009,1,6]],"date-time":"2009-01-06T01:53:36Z","timestamp":1231206816000},"page":"1039-1047","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":43,"title":["Detection of Molecular Markers of Antiviral Resistance in Influenza A (H5N1) Viruses Using a Pyrosequencing Method"],"prefix":"10.1128","volume":"53","author":[{"given":"Varough M.","family":"Deyde","sequence":"first","affiliation":[{"name":"Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tung","family":"Nguyen","sequence":"additional","affiliation":[{"name":"National Centre for Veterinary Diagnostics, DAH11-78th lane, Giai Phong str Phuong Mai, Dong Da, Hanoi, Vietnam"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rick A.","family":"Bright","sequence":"additional","affiliation":[{"name":"Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Balish","sequence":"additional","affiliation":[{"name":"Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Shu","sequence":"additional","affiliation":[{"name":"Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Lindstrom","sequence":"additional","affiliation":[{"name":"Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander I.","family":"Klimov","sequence":"additional","affiliation":[{"name":"Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larisa V.","family":"Gubareva","sequence":"additional","affiliation":[{"name":"Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0707279"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2007.08.008"},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.antiviral.2007.01.006","volume":"75","year":"2007","unstructured":"Barr, I. G., A. C. Hurt, N. Deed, P. Iannello, C. Tomasov, and N. Komadina. 2007. The emergence of adamantane resistance in influenza A(H1) viruses in Australia and regionally in 2006. Antivir. Res.75:173-176.","journal-title":"Antivir. Res."},{"key":"e_1_3_2_5_2","first-page":"112","volume":"73","year":"2006","unstructured":"Barr, I. G., A. C. Hurt, P. Iannello, C. Tomasov, N. Deed, and N. Komadina. 2006. Increased adamantane resistance in influenza A(H3) viruses in Australia and neighbouring countries in 2005. Antivir. Res.73:112-117.","journal-title":"Antivir. Res."},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1086\/508777"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1086\/338870"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67338-2"},{"key":"e_1_3_2_9_2","first-page":"44","volume":"55","year":"2006","unstructured":"Bright, R. A., D. Shay, J. Bresee, A. Klimov, N. Cox, and J. R. Ortiz. 2006. High levels of adamantane resistance among influenza A (H3N2) viruses and interim guidelines for use of antiviral agents\u2014United States, 2005-2006 influenza season. MMWR Morb. Mortal. Wkly. Rep.55:44-46.","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.8.joc60020"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm8001197"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1086\/504723"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(98)00005-X"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature06956"},{"key":"e_1_3_2_15_2","first-page":"554","volume":"389","year":"1997","unstructured":"de Jong, J. C., E. C. Claas, A. D. Osterhaus, R. G. Webster, and W. L. Lim. 1997. A pandemic warning? Nature389:554.","journal-title":"Nature"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa054512"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2008.08.008"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1086\/518936"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jviromet.2008.07.017"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2007.10.020"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)11433-8"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-3542(01)00192-9"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/18.Supplement_B.19"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2006.05.016"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2007.08.007"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2006.10.004"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16934-1"},{"key":"e_1_3_2_28_2","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1177\/135965350801300602","volume":"13","year":"2008","unstructured":"Lackenby, A., J. Democratis, M. M. Siqueira, and M. C. Zambon. 2008a. Rapid quantitation of neuraminidase inhibitor drug resistance in influenza virus quasispecies. Antivir. Ther.13:809-820.","journal-title":"Antivir. Ther."},{"key":"e_1_3_2_29_2","first-page":"pii=8026","volume":"13","year":"2008","unstructured":"Lackenby, A., O. Hungnes, S. G. Dudman, A. Meijer, W. J. Paget, A. J. Hay, and M. C. Zambon. 31 January 2008. Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe. Eurosurveillance13(5):pii=8026. http:\/\/www.eurosurveillance.org\/ViewArticle.aspx?ArticleId=8026 .","journal-title":"Eurosurveillance"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/4371108a"},{"key":"e_1_3_2_31_2","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nature05003","volume":"443","year":"2006","unstructured":"Luo, M. 2006. Structural biology: antiviral drugs fit for a purpose. Nature443:37-38.","journal-title":"Nature"},{"key":"e_1_3_2_32_2","first-page":"103","year":"2001","unstructured":"Macken, C., H. Lu, J. Goodman, and L. Boykin. 2001. The value of a database in surveillance and vaccine selection, p. 103-106. In A. D. M. E. Osterhaus, N. Cox, and A. W. Hampson (ed.), Options for the control of influenza, vol. IV. Elsevier Science, Amsterdam, The Netherlands.","journal-title":"Options for the control of influenza"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid1309.070164"},{"key":"e_1_3_2_34_2","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1086\/422646","volume":"39","year":"2004","unstructured":"Monto, A. S., J. Rotthoff, E. Teich, M. L. Herlocher, R. Truscon, H. L. Yen, S. Elias, and S. E. Ohmit. 2004. Detection and control of influenza outbreaks in well-vaccinated nursing home populations. Clin. Infect. Dis.39:459-464.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra050740"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1637\/0005-2086-47.s3.1141"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2004.02.033"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00645-06"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature05114"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc062989"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.20946"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00555-08"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.279.5349.393"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1099-1654(200001\/02)10:1<45::AID-RMV265>3.0.CO;2-R"},{"key":"e_1_3_2_45_2","doi-asserted-by":"crossref","first-page":"i5","DOI":"10.1093\/jac\/dki018","volume":"55","year":"2005","unstructured":"Ward, P., I. Small, J. Smith, P. Suter, and R. Dutkowski. 2005. Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. J. Antimicrob. Chemother.55(Suppl. 1):i5-i21.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.41.2.742-750.2003"},{"key":"e_1_3_2_47_2","unstructured":"Cumulative number of confirmed human cases of avian influenza A\/(H5N1) reported to WHO. 2009"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00959-08"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01067-07"},{"key":"e_1_3_2_50_2","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1021\/ci800041k","volume":"48","year":"2008","unstructured":"Zhang, Q., J. Yang, K. Liang, L. Feng, S. Li, J. Wan, X. Xu, G. Yang, D. Liu, and S. Yang. 2008. Binding interaction analysis of the active site and its inhibitors for neuraminidase (N1 subtype) of human influenza virus by the integration of molecular docking, FMO calculation and 3D-QSAR CoMFA modeling. J. Chem. Inf. Model.48:1802-1812.","journal-title":"J. Chem. Inf. Model."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01446-08","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01446-08","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T11:06:40Z","timestamp":1684840000000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01446-08"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,3]]}},"alternative-id":["10.1128\/AAC.01446-08"],"URL":"https:\/\/doi.org\/10.1128\/aac.01446-08","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,3]]},"assertion":[{"value":"2008-10-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2008-12-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2009-03-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}